Moreover, antibodies against PD-L1, TIM-3, or LAG3 restore responses of HCC-derived T cells to tumor antigens, and combinations of these antibodies have additive effects, suggesting that blocking those signaling pathways might benefit patients with primary liver cancer [122]. Here, LAG3 is linked to hepatocellular carcinoma.